https://allsci.com/news/clinical-trials/celiac-disease-treatment-antibody-tevas/ AllScien 2026-09-02T12:59:38.639223Z Teva's anti-IL-15 antibody cuts gluten-induced intestinal damage in Phase IIa celiac disease trial https://allsci.com/news/clinical-trials/rzl-012-phase-iii-submental-fat-raziels-meets/ AllScien 2026-09-02T11:53:57.289935Z Raziel's RZL-012 meets Phase III endpoints for submental fat reduction, paving China NDA path https://allsci.com/news/corporate-strategy/vertex-crinetics-acquisition-closes-usd-10b-deal/ AllScien 2026-09-02T11:42:47.858580Z Vertex closes USD 10b Crinetics deal to establish endocrinology as fifth therapeutic pillar https://allsci.com/news/first-in-human-trials/cdh17-antibody-gastric-cancer-bighats-ai-designed/ AllScien 2026-09-02T11:39:04.457274Z BigHat's AI-designed CDH17 antibody enters human testing for gastric cancer https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-neurological-ono-pharma-taps/ AllScien 2026-09-02T11:20:56.668471Z Ono Pharma taps Aitia's causal AI to identify neurological disease targets https://allsci.com/news/licensing-and-partnerships/t-cell-engager-therapy-solid-tumors-evotec-and/ AllScien 2026-09-02T10:53:26.491570Z Evotec and Plectonic combine T-cell platforms to tackle solid tumor selectivity challenge https://allsci.com/news/licensing-and-partnerships/egfr-inhibitor-lung-cancer-pharos-ibio-and-kolon/ AllScien 2026-09-02T10:27:04.868346Z Koirea's Pharos iBio, Kolon Pharma advance fourth-generation EGFR inhibitor into preclinical https://allsci.com/news/regulatory/fda-breakthrough-hypoxia-cancer-junipers-tracer/ AllScien 2026-09-01T18:11:21.836076Z FDA grants breakthrough status to Juniper hypoxia tracer for radiation de-escalation in HPV-positive OPC https://allsci.com/news/clinical-trials/gene-therapy-geographic-atrophy-ocugen-launches/ AllScien 2026-09-01T18:07:46.507638Z Ocugen launches Phase III trial of one-time gene therapy for geographic atrophy https://allsci.com/news/clinical-trials/envudeucitinib-lupus-trial-fails-phase-iib-but/ AllScien 2026-09-01T18:03:42.079676Z Envudeucitinib misses Phase IIb lupus endpoints, subgroup signal keeps program alive https://allsci.com/news/clinical-trials/remibrutinib-multiple-sclerosis-novartiss-beats/ AllScien 2026-09-01T18:01:31.831597Z Novartis's remibrutinib beats teriflunomide across Phase III relapsing MS trials https://allsci.com/news/clinical-trials/biontech-colorectal-cancer-trial-terminates/ AllScien 2026-09-01T17:30:07.053894Z BioNTech halts personalized mRNA cancer vaccine trial in CRC after survival imbalance https://allsci.com/news/patents-ip/patent-infringement-verdict-10x-genomics-wins/ AllScien 2026-09-01T15:09:45.028040Z 10x wins USD 4.8m willful-infringement verdict against Qiagen-owned Parse https://allsci.com/news/clinical-trials/savolitinib-tagrisso-lung-cancer-plus-meets/ AllScien 2026-09-01T14:54:08.812936Z Savolitinib plus Tagrisso hits first-line PFS goal in MET-overexpressing EGFR-mutated lung cancer https://allsci.com/news/venture-financing/protein-degradation-platform-convergen-raises-usd/ AllScien 2026-09-01T14:47:04.344753Z Convergen raises USD 15m to advance tau-targeting protein degradation platform https://allsci.com/news/venture-financing/eit-pharma-series-a-funding-secures-usd-35m-to/ AllScien 2026-09-01T14:38:03.674798Z EIT Pharma secures USD 35m Series A to advance lonafarnib in hepatitis D https://allsci.com/news/funding/kazia-paxalisib-funding-raises-usd-40m-upfront/ AllScien 2026-09-01T14:30:21.047374Z Kazia raises USD 40m upfront, links another USD 80m to breast cancer readouts https://allsci.com/news/funding/pmv-pharma-funding-rezatapopt-raises-usd-508m-to/ AllScien 2026-09-01T14:23:36.028018Z PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027 https://allsci.com/news/approvals/stelara-pediatric-ulcerative-colitis-fda-expands/ AllScien 2026-09-01T14:18:59.106597Z FDA expands Stelara into pediatric ulcerative colitis with non-TNF mechanism https://allsci.com/news/approvals/besremi-fda-approval-essential-thrombocythemia/ AllScien 2026-09-01T14:15:50.248514Z FDA approves Besremi for essential thrombocythemia, first new ET drug in nearly 30 years https://allsci.com/news/corporate-strategy/redhill-talicia-divestment-exits-pylori-therapy/ AllScien 2026-09-01T14:11:40.731166Z RedHill exits Talicia for USD 18m upfront to fund GI portfolio expansion https://allsci.com/news/clinical-trials/recombinant-botulinum-toxin-revelyx-launches-with/ AllScien 2026-09-01T13:40:05.331996Z Revelyx launches with recombinant botulinum toxin ready for Phase II readout https://allsci.com/news/pharma/lilly-merida-acquisition-autoimmune-acquires/ AllScien 2026-09-01T13:29:09.781461Z Lilly snaps up Merida in USD 2.9b autoimmune deal https://allsci.com/news/approvals/enhertu-pertuzumab-her2-breast-cancer-plus/ AllScien 2026-09-01T12:04:58.580532Z Enhertu plus pertuzumab breaks decade-long first-line HER2-positive breast cancer status quo https://allsci.com/news/licensing-and-partnerships/roche-simcere-antibody-license-licenses-simceres/ AllScien 2026-09-01T11:59:49.109180Z Roche bets USD 1.53 billion on Simcere’s trispecific T-cell engager https://allsci.com/news/clinical-trials/acoramidis-attr-cm-cardiac-reverses-damage-in/ AllScien 2026-09-01T09:57:34.388242Z Acoramidis shows signs of cardiac remodeling reversal in ATTR-CM CMR analysis https://allsci.com/news/approvals/mimrylo-fda-approval-polycythemia-vera-approves/ AllScien 2026-09-01T09:09:54.326999Z FDA approves Takeda's Mimrylo as first hepcidin mimetic for polycythemia vera https://allsci.com/news/clinical-trials/vutrisiran-tafamidis-attr-cm-maintains-mortality/ AllScien 2026-09-01T08:59:31.210996Z Vutrisiran shows consistent HELIOS-B benefit regardless of tafamidis use https://allsci.com/news/clinical-trials/mavacamten-obstructive-hypertrophic-cardiomyopathy/ AllScien 2026-09-01T08:54:07.672499Z Five-year Camzyos data show sustained oHCM benefit as aficamten competition emerges https://allsci.com/news/clinical-trials/cardiac-amyloidosis-pet-tracer-bayers-meets-dual/ AllScien 2026-09-01T08:08:30.817064Z Bayer’s evuzamitide posts 94% sensitivity in Phase III cardiac amyloidosis study https://allsci.com/news/licensing-and-partnerships/leios-10xb-101-licensing-agreement-licenses-to/ AllScien 2026-09-01T07:56:19.702014Z Leios hands Greater China rights to Phase III fat reduction drug to CMS https://allsci.com/news/licensing-and-partnerships/opti-mab-platform-antibody-aax-biotech-advances/ AllScien 2026-09-01T07:49:17.330018Z Daiichi Sankyo advances AAX Biotech’s Opti-mAb into antibody program